CN107485790A - It is a kind of to utilize the apparatus for curing insomnia for integrating the micro- magnetic field of ripple - Google Patents
It is a kind of to utilize the apparatus for curing insomnia for integrating the micro- magnetic field of ripple Download PDFInfo
- Publication number
- CN107485790A CN107485790A CN201610409998.XA CN201610409998A CN107485790A CN 107485790 A CN107485790 A CN 107485790A CN 201610409998 A CN201610409998 A CN 201610409998A CN 107485790 A CN107485790 A CN 107485790A
- Authority
- CN
- China
- Prior art keywords
- mrow
- insomnia
- sleep
- mtd
- electromagnetic waves
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 87
- 206010022437 insomnia Diseases 0.000 title claims abstract description 84
- 208000024891 symptom Diseases 0.000 claims abstract description 39
- 230000003860 sleep quality Effects 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 7
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000007958 sleep Effects 0.000 description 72
- 238000000034 method Methods 0.000 description 28
- 206010062519 Poor quality sleep Diseases 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 11
- 208000002173 dizziness Diseases 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000147 hypnotic effect Effects 0.000 description 9
- 206010008479 Chest Pain Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 208000019116 sleep disease Diseases 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000007661 gastrointestinal function Effects 0.000 description 6
- 208000020685 sleep-wake disease Diseases 0.000 description 6
- 230000002618 waking effect Effects 0.000 description 6
- 231100000862 numbness Toxicity 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000004622 sleep time Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 4
- 210000000323 shoulder joint Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003326 hypnotic agent Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 206010029412 Nightmare Diseases 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- -1 medazapam Chemical compound 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 208000024335 physical disease Diseases 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 241001166076 Diapheromera femorata Species 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001282135 Poromitra oscitans Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 229960002200 flunitrazepam Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003188 temazepam Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 229960004010 zaleplon Drugs 0.000 description 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960000820 zopiclone Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M21/02—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H2039/005—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture by means of electromagnetic waves, e.g. I.R., U.V. rays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/12—Driving means
- A61H2201/1207—Driving means with electric or magnetic drive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0055—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with electric or electro-magnetic fields
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Rehabilitation Therapy (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Acoustics & Sound (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of using the apparatus for curing insomnia for integrating the micro- magnetic field of ripple, it includes an electromagnetic wave generator that can apply electromagnetic wave to patient, and the waveform of the electromagnetic wave is: 300 μ sec≤τ≤0.02sec, 5msec≤t1≤0.1sec.Wherein, τ is equal to time constant caused by generator in drive circuit;T represents any time point;(t1T) duration or working time of pulse are represented;ImaxThe maximum DC electric current of circuit is flowed through in expression, and the electromagnetic wave is effectively reduced the clinical symptoms of the patient with insomnia.
Description
Technical Field
The invention relates to an insomnia therapeutic apparatus, in particular to an insomnia therapeutic apparatus using an integral wave micro-magnetic field.
Background
Insomnia is one of the most common clinical diseases, which means difficulty in falling asleep, difficulty in maintaining sleep at night and early awakening, and is insufficient or poor in sleep quality. Insomnia causes the brain of a person to have insufficient rest, affects normal work and life, and induces physical diseases such as heart, brain and the like. Insomnia can be classified into primary and secondary types according to its etiology.
1. Primary insomnia: usually, there is a lack of clear etiology or insomnia symptoms remain after eliminating the etiology that may cause insomnia, mainly including psychophysiological insomnia, idiopathic insomnia and subjective insomnia of 3 types. The diagnosis of primary insomnia lacks specific indexes, and is mainly an exclusionary diagnosis. Primary insomnia is considered to be caused when insomnia symptoms remain after the etiology that may cause insomnia is eliminated or cured. According to the psychological and physiological insomnia, the etiology can be traced to the influence of a certain or long-term event on the functional stability of the peripheral system of the brain of a patient, and the imbalance of the functional stability of the peripheral system finally causes the disorder of the brain sleep function and the insomnia.
2. Secondary insomnia: including insomnia due to physical diseases, mental disorders, drug abuse, etc., and insomnia associated with sleep disordered breathing, sleep movement disorders, etc. Insomnia frequently occurs simultaneously with other diseases, and sometimes it is difficult to determine the causal relationship between these diseases and insomnia, so in recent years the concept of comorbidinsomnia has been proposed to describe those insomnia that are accompanied simultaneously with other diseases.
The diagnosis of insomnia has the following two criteria:
1. western diagnostic criteria: refer to the diagnostic criteria for patients with primary insomnia in the manual for diagnosis and statistics of mental disorders (DSM-IV) in the United states: (1) complaining of difficulty in falling asleep and maintaining sleep, with onset of illness for at least 1 month; (2) sleep disorders cause distress or social, occupational, etc. disorders; (3) the sleep disorder is eliminated due to narcolepsy, sleep disorder related to respiration, sleep disorder of biological rhythm and the like; (4) the sleep disorder is caused by major depression, generalized anxiety and other disorders; (5) sleep disorder is excluded from being caused by various somatic diseases, psychological effects of alcohol or drugs.
2. The traditional Chinese medicine diagnosis standard is as follows: referring to the clinical research guidelines of traditional Chinese medicine (1), the traditional Chinese medicine has typical symptoms of insomnia: difficulty in falling asleep, often arousing, vigorous and unstable or failing to sleep again after waking up; waking up in the morning; the user can not fall asleep at night and is deep and sleepy in the daytime; sleep for less than 5 hours. (2) There was a history of recurrent episodes.
The long-term insomnia taking of the hypnotic medicine is harmful to the health, and the hypnotic medicine has certain toxicity, so that the function of liver secretory enzyme is damaged, the liver function is reduced, and the dysfunction of liver, kidney and even five internal organs is brought. In addition, the drug resistance of human bodies is caused by long-term administration, the medicine can not be taken out, the more the medicine is taken, and the serious dependence is generated.
Therefore, the development of a new physical therapy which is harmless to the body for treating insomnia has great practical value.
Disclosure of Invention
The invention aims to overcome the defect of insomnia treatment in the prior art, and provides an insomnia treatment instrument using an integral wave micro-magnetic field, which comprises an electromagnetic wave generator capable of applying electromagnetic waves to a patient, wherein the waveform of the electromagnetic waves is as follows:
300μsec≤τ≤0.02sec,
5msec≤t1≤0.1sec。
wherein,
τ is equal to the time constant generated by the generator in the drive circuit;
t represents any point in time;
(t1-t) represents the duration or on-time of the pulse;
Imaxrepresenting the maximum DC current flowing through the circuit,
the electromagnetic waves are effective to reduce clinical symptoms in patients with insomnia.
In another preferred embodiment, ImaxThe range of Imax is more than or equal to 50mA and less than or equal to 200 mA.
In another preferred embodiment, τ and t1The ranges of (A) are as follows:
a)8.15msec≤τ≤12.15msec,
b)42.5msec≤t1≤62.5msec。
in another preferred example, the frequency of the electromagnetic wave is between 20Hz and 120 Hz.
In another preferred example, the electromagnetic waves are applied to the Yongquan point of the left and right feet and/or the Laogong point of the left and right hands of the patient.
In another more preferred embodiment, the electromagnetic waves are applied to the Yongquan Point on the left and right feet and/or the Laogong Point on the left and right hands of the patient at least once a day for 8-20 minutes each.
In another more preferred embodiment, the electromagnetic waves are applied to the patient's right and left foot Yongquan points and/or right and left hand Laogong points twice daily for 8-20 minutes each.
In another more preferred embodiment, the electromagnetic waves are applied to the patient's left and right foot yongquan points and/or left and right hand laogong points three times a day for 8-20 minutes each.
In another preferred example, the electromagnetic waves are effective to reduce the Tzburg sleep quality index (PSQI) score of a patient suffering from insomnia.
In another more preferred example, the electromagnetic wave is effective to reduce the PSQI score of a patient suffering from insomnia by 5 points or more. In another more preferred example, the electromagnetic waves are effective to reduce the PSQI score of a patient suffering from insomnia by 6 points or more. In another more preferred example, the electromagnetic waves are effective to reduce the PSQI score of a patient suffering from insomnia by 7 points or more. In another more preferred example, the electromagnetic waves are effective to reduce the PSQI score of a patient suffering from insomnia by 8 points or more. In another more preferred example, the electromagnetic wave is effective to reduce the PSQI score of a patient suffering from insomnia by 9 points or more. In another more preferred example, the electromagnetic waves are effective to reduce the PSQI score of a patient suffering from insomnia by 10 points or more. In another more preferred example, the electromagnetic waves are effective to reduce the PSQI score of a patient suffering from insomnia by 12 points or more. In another more preferred example, the electromagnetic waves are effective to reduce the PSQI score of a patient suffering from insomnia by 15 points or more.
In another preferred embodiment, the electromagnetic waves are used as a monotherapy for treating insomnia.
In another preferred example, the electromagnetic wave is used as an adjuvant therapy for treating insomnia.
In another more preferred embodiment, the electromagnetic waves are used with a drug for treating insomnia.
In another more preferred embodiment, the medicament for treating insomnia is common western medicines for treating insomnia, such as triazolam, midazolam, medazapam, lorazepam, temazepam, alprazolam, estazolam, oxazepam, flunitrazepam, diazepam, nitrazepam, clonazepam, halozazolam, zolpidem, zopiclone, zaleplon and the like, and common traditional Chinese medicines for treating insomnia, such as capsule dormancy.
The specific contents of the Pittsburgh Sleep Quality Index (PSQI) in the invention are as follows:
guidance language: some of the following questions are about the last month of sleep, please fill in or select the answer that best fits your actual situation.
1. The sleep time in bed is usually ____ o' clock in the evening for nearly 1 month.
2. In the last 1 month, ____ minutes are usually needed from getting to bed to falling asleep.
3. In the last 1 month, the patient usually gets up in the morning at ____ points.
4. Approximately 1 month, a typical actual sleep time of ____ hours per night
The answer that best fits you is selected for the following question.
5. In the last month, you have trouble not affecting sleep
a. Difficulty in falling asleep (the person cannot fall asleep within 30 minutes), namely, no (1) week, (1) to (2) weeks, (not less than or equal to (3) weeks
b. Easy or early waking at night (1 week, 1-2 weeks, 3 weeks)
c. Night toilet removal (1 week, 1-2 weeks, 3 weeks)
d. Unsmooth breathing (1 week), (1 to 2 weeks), (3 weeks)
e. High cough or snore sound (1 week, 1-2 weeks, 3 weeks)
f. Cold feeling (1 week), (1-2 weeks), (3 weeks)
g. Heat sensation (1 week, 1 to 2 weeks, 3 weeks)
h. Nightmare (a nightmare) is performed for 1 week, 1-2 weeks, and ≧ 3 weeks
i. Pain discomfort (1 week, 1-2 weeks, 3 weeks)
j. Other things influencing sleep (1 week, 1-2 weeks, 3 weeks and so on)
If yes, please explain:
6. in nearly 1 month, generally, you think that the sleep quality of oneself is good (good), (bad)
7. Nearly 1 month, the hypnotic drugs are used for 1 week, 1 to 2 weeks, 3 weeks and less
8. In the last 1 month, do you feel drowsy? Not less than 1 week, 1 to 2 weeks, not less than 3 weeks
9. In nearly 1 month, people feel that the efforts are insufficient (good), (bad)
Use and statistical methods: PSQI was used to assess the quality of sleep over the last 1 month of the test. The 18 items form 7 components, each component is scored according to the grade of 0-3, the score of each component is accumulated to be PSQI total score, the total score range is 0-2 l, and the higher the score is, the worse the sleep quality is. The testee needs 5-10 minutes to complete the trial.
The contents and the scoring method of the components are as follows:
quality of sleep A:
score 1 based on the response score of entry 6 "better," score 2 based on "worse," score 3 based on "worse.
Time to fall asleep
The item 2 is scored as 0 point less than or equal to 15 points, 1 point is scored as 16-30 points, 2 points are scored as 31-60 points, and 3 points are scored as 60 points.
The score of the item 5a is 0 points for "none", "1 points for" <1 week/time "," 2 points for 1-2 weeks/time ", and 3 points for" ≧ 3 weeks/time ".
Accumulating the scores of the items 2 and 5a, if the accumulated score is 0, 1 to 2, 3 to 4, 2 and 3
C sleep time
According to the response score of item 4, "> 7 hours" is counted as 0 score, "6 to 7" is counted as 1 score, "5 to 6" is counted as 2 score, and "< 5 hours" is counted as 3 score.
Sleep efficiency
Time on bed-entry 3 (getting up time) -entry 1 (time on bed)
Sleep efficiency ═ entry 4 (sleep time)/time in bed × 100%
The component D is counted into a score, the sleeping efficiency is more than 85%, the sleeping efficiency is 0 score, 75-84% is 1 score, 65-74% is 2 score, and < 65% is 3 score.
Sleep disorder E
The scores were 0 score for "none", 1 score for "< 1 week/time", "2 scores for 1-2 weeks/time", and 3 scores for "≧ 3 weeks/time", based on the scores of the items 5b to 5 j. The scores of items 5b to 5j are accumulated, and if the accumulated score is "0", the score of component E is 0, the score of "1 to 9", the score of "10 to 18", the score of 2 ", and the score of" 19 to 27 "is 3.
F hypnotic
According to the response score of item 7, "none" is counted as 0 point, "< 1 week/time" is counted as 1 point, 1-2 weeks/time "is counted as 2 points, and" ≧ 3 weeks/time "is counted as 3 points.
G daytime dysfunction:
according to the response score of item 7, "none" is counted as 0 point, "< 1 week/time" is counted as 1 point, 1-2 weeks/time "is counted as 2 points, and" ≧ 3 weeks/time "is counted as 3 points.
According to the response score of item 7, "none" counts 0, occasionally "counts 1, occasionally" counts 2, and "often" counts 3.
The scores of items 8 and 9 are accumulated, and if the accumulated score is "0", the score of component G is 0, the score of "1-2", the score of "3-4", the score of 2 ", and the score of" 5-6 ", the score of 3
The PSQI total is component A + component B + component C + component D + component E + component F + component G.
The insomnia therapeutic apparatus of the invention has the following action principle: the electromagnetic wave generated by the electromagnetic wave acts on the Laogong acupoint and the Yongquan acupoint to send an acute traumatic regenerative current code signal, and acts on a cerebral nervous system, so that the following effects can be achieved: 1. promoting the generation of vascular endothelial progenitor cells and repairing damaged blood vessels; 2. promote increased production of NO and eNO, which has the following sleep-promoting effects: mediating to produce various sleep factors to promote sleep, promote the release of sleep-promoting neurotransmitter, and regulate the synthesis of sleep-promoting substances; 3. promoting blood circulation of brain, increasing oxygen supply of local blood vessel, and improving cerebral blood supply deficiency.
The insomnia therapeutic apparatus of the invention has the following technical effects:
can effectively improve insomnia, and has no side effect and no dependence.
Detailed Description
The following examples section will illustrate the invention. This section of the description will help those skilled in the art to understand the invention more deeply, but should not be construed as limiting what is set forth in the claims.
Detailed description of the experiments
Example 1:
and (3) clinical trials: the treatment effect of the insomnia treatment instrument of the present invention on patients with insomnia was evaluated:
503 patients who used the insomnia therapeutic apparatus of the present invention on the basis of the original treatment or no treatment were followed up.
Duration of treatment: 3 months.
Application method:
Inclusion/exclusion:
inclusion case criteria:
the Chinese and western medicine diagnosis standards are met;
pittsburgh sleep quality scale (PSQI) score >7 points;
the patients who have not used the medicine with serious influence on liver and kidney functions within 3 months.
Exclusion criteria for cases:
insomnia is caused by systemic diseases such as pain, fever, cough, operation and the like, and external environmental interference factors;
pregnant or lactating women;
those with allergic constitution or a history of drug allergy;
patients with serious primary diseases such as heart, liver, kidney, hematopoietic system and endocrine system, and psychosis are complicated.
There are alcoholism and/or psychoactive substances, drug abuse and dependence (including hypnotic drugs).
Result index: the reduction of the Pittsburgh Sleep Quality Index (PSQI) is not less than 5 points.
Results: the accompanying results show that 82.16% of patients considered the insomnia treatment apparatus of the present invention to be effective.
Example 2:
follow-up results of specific cases:
case 1
Name: money XX, gender: female, age: age 62 years old
The main symptoms are as follows: hypertension (slightly high upper pressure) and hyperglycemia (8.5) have poor sleep (about 7 years), sleep is maintained for about 2 hours by taking hypnotics all the time, the face color is dark, and headache is often caused.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 6 months.
The treatment results are as follows: stable blood pressure and 6.5 blood sugar, sleep for about 4 hours (no hypnotics), white and fat face.
As a result: is obviously effective.
Case 2
Name: XXX, sex: female, age: age X
The main symptoms are as follows: glaucoma, high ocular pressure, shallow sleep, waking up in the middle of the night, premature beat, slight cerebral infarction and more than 90-150 times of cumulative blood pressure.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 6 months.
The treatment results are as follows: the insomnia therapeutic apparatus of the invention can sleep well after 2 months, and is not like the prior insomnia therapeutic apparatus which is easy to wake up, and the sleep is more comfortable.
As a result: is obviously effective.
Case 3
Name: XXX, sex: female, age: age 45
The main symptoms are as follows: thyroid nodules and poor sleep.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 4 months.
The treatment results are as follows: the sleep is improved, the face color is ruddy and glossy, the gastrointestinal functions are normal, the original full-head white hair (heredity) has black hair which slowly grows out, and the hair thinning caused by frequent hair dyeing is also changed.
As a result: is obviously effective.
Case 4
Name: XXX, sex: male, age: 71
The main symptoms are as follows: hypertension and insomnia, the patient can not sleep after being awakened frequently in the middle of the night, and the patient gets up to read at 2 and 3 o' clock in the middle of the night.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 20 consecutive days.
The treatment results are as follows: the sleep is good, the user can not sleep after waking up the sleeping bag in the middle of the night, and the user can sleep in the toilet in the middle of the night to be bright.
As a result: is obviously effective.
Case 5
Name: XXX, sex: x, age: x
The main symptoms are as follows: dizziness and insomnia.
Treatment of the condition: the Yongquan acupoint on the left and right feet and the Laogong acupoint on the left and right hands are respectively used once a day in the first week, and the Yongquan acupoint on the left and right feet and the Laogong acupoint on the left and right hands are respectively used twice a day after a week, each time is 8-20 minutes, and the application lasts for 3 months.
The treatment results are as follows: the sleep is improved well, the user can fall asleep within half an hour after getting up at night, and dizziness and weakness are improved greatly when getting up at night for more than three times and less than once every day.
As a result: is obviously effective.
Case 6
Name: XXX, sex: x, age: x
The main symptoms are as follows: the sleep is insufficient, and the patient wakes up at 2 o 'clock of sleeping at 10 o' clock every day.
Treatment of the condition: the preparation is administered three times a day in the morning, at noon and at night, each time for 8 min, and continuously for 3 days.
The treatment results are as follows: yesterday is awakened at 5 points, today wakes up at 3 points in the middle of the night, and sleeps again by using the insomnia therapeutic apparatus, and the user does not know when changing hands and awakens at six points in the morning.
As a result: is obviously effective.
Case 7
Name: red female, gender: female, age: 73 years old
The main symptoms are as follows: 1. the sleep quality is poor, and the user cannot fall asleep after waking up at 2 or 3 o' clock every night; 2. the blood pressure is higher by 90-160%; 3. gastritis; 4. severe premature beat; 5. often times, oral ulcers.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 13 months.
The treatment results are as follows: the sleep of the sleep therapeutic apparatus of the invention is greatly improved in the first month, and the sleep is kept at more than 5 points every day, so that the mental state is obviously improved in the daytime, and the face is ruddy; 2. blood pressure is basically normal 70-140 in the 5 th month of the year, and the medicine is stopped until now under the suggestion of doctors; 3. the stomach burp gas has completely improved; 4. premature beats are currently sporadic; 5. the frequent oral ulcer symptoms with the improved immunity are thoroughly improved, and the symptoms do not occur in the next half of the year.
As a result: is obviously effective.
Case 8
Name: XXX, sex: female, age: x
The main symptoms are as follows: insomnia, which can only sleep for 2 and 3 hours every day.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 3 months.
The treatment results are as follows: sleeping for 6 to 7 hours every day, and sleeping for 2 noons and more hours in the afternoon.
As a result: is obviously effective.
Case 9
Name: women, gender: female, age: 55
The main symptoms are as follows: dizziness, chest distress, poor sleep quality, shallow sleep, blood pressure 160/85, poor gastrointestinal function absorption and easy fatigue.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 2 months.
The treatment results are as follows: the insomnia therapeutic apparatus has the advantages that the sleep is obviously improved in half a month, the sleep can be improved to deep sleep for 4-5 hours every day in 2 months, the phenomena of dizziness and chest distress are obviously improved, the feeling of fatigue is not existed, the fine lines on the face are reduced, the melanin spots are faded, the gastrointestinal function is obviously improved, the constipation phenomenon is not existed, and the blood pressure is reduced to 142/83.
As a result: is obviously effective.
Case 10
Name: XXX, sex: x, age: x
The main symptoms are as follows: pain in the joints of the rattan and other joints, pain in the cervical vertebrae, discomfort in the stomach, inability to move when eating rice, regurgitation, vomiting, inability to walk without using a walking stick, and inability to fall asleep due to numbness of legs and feet.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 3 months.
The treatment results are as follows: the joint pain is greatly relieved, the stomach is comfortable, the stomach is not regurgitated, the walking can be performed without a crutch, the leg numbness is obviously improved, and the sleep is improved.
As a result: is obviously effective.
Case 11
Name: XXX, sex: male, age: XX
The main symptoms are as follows: hypertension, poor sleep and inability to sleep deeply in the night.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 1 month.
The treatment results are as follows: the blood pressure is stable, the sleep is improved greatly, and the deep sleep can be realized at night.
As a result: is obviously effective.
Case 12
Name: XXX, sex: female, age: and (4) X.
The main symptoms are as follows: the sleep is poor at ordinary times when the blood pressure is higher than 140% and lower than 85%, and the sleep can be only performed for 2-3 hours at night and is light sleep.
Treatment of the condition: following the procedure set forth in example 1, use was continued for 1 more months.
The treatment results are as follows: the blood pressure is normal and the patient can sleep for 4 hours.
As a result: is obviously effective.
Case 13 (American user)
Name: XXX, sex: x, age: x
The main symptoms are as follows: the sleep quality is poor.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 3 months.
The treatment results are as follows: the sleep quality is improved.
As a result: is obviously effective.
Case 14 (Australian user)
Name: XXX, sex: x, age: x
The main symptoms are as follows: the sleep quality is poor.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 3 months.
The treatment results are as follows: the sleep quality is improved.
As a result: is obviously effective.
Case 15
Name: XXX, sex: x, age: age 80
The main symptoms are as follows: severe insomnia, which can only fall asleep at 5 am every day.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 17 consecutive days.
The treatment results are as follows: the sleep quality is improved.
As a result: is obviously effective.
Case 16
Name: XXX, sex: x, age: x
The main symptoms are as follows: the sleep quality is not good, and hypnotic drugs need to be taken during sleep.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 2 months.
The treatment results are as follows: sleep does not need to take hypnotics any more.
As a result: is obviously effective.
Case 17
Name: XXX, sex: female, age: age 55
The main symptoms are as follows: poor sleep quality, high triglyceride, high low density lipoprotein, dizziness, chest distress, heart T wave, pain and numbness in the waist, neck and shoulder joints.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 4 months.
The treatment results are as follows: the sleep therapeutic apparatus of the invention has the advantages of obvious improvement of sleep in about 1 month, obvious fading of facial pigment, no phenomena of dizziness and chest distress in about 2 months, and obvious auxiliary curative effects of blood pressure, heart and brain, liver and gallbladder, gastrointestinal functions, vascular repair, rehabilitation of waist, neck and shoulder joint pain and the like by CsR detection body cell depth scanning data in about 4 months.
As a result: is obviously effective.
Case 18
Name: old XX, gender: female, age: x
The main symptoms are as follows: soreness and pain in the hands and feet, and high and tense sleep.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 3 months.
The treatment results are as follows: the sleep is obviously improved, and the aching pain of hands and feet is much better.
As a result: is obviously effective.
Case 19
Name: XXX, sex: x, age: x
The main symptoms are as follows: poor sleep quality, arrhythmia.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 2 months.
The treatment results are as follows: poor sleep quality and arrhythmia are improved obviously, and the weight is increased.
As a result: is obviously effective.
Case 20
Name: XXX, sex: x, age: x
The main symptoms are as follows: the people can not sleep slowly, sleep for more than 50 minutes deeply, and feel cold in hands.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 2 months.
The treatment results are as follows: the people can sleep quickly, fall asleep for a lot of time, sleep deeply for two or more hours, and have 2 hours and 36 minutes in one day, so that the people are full of energy, warm and cool.
As a result: is obviously effective.
Case 21
Name: XXX, sex: x, age: x
The main symptoms are as follows: the sleep quality is poor.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 3 consecutive days.
The treatment results are as follows: the sleep quality is improved.
As a result: is obviously effective.
Case 22
Name: money XX, gender: female, age: 65 years old
The main symptoms are as follows: poor sleep for a long time, low blood sugar, low blood pressure, high cholesterol and poor cervical vertebra.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 5 months. .
The treatment results are as follows: the sleep is improved.
As a result: is obviously effective.
Case 23
Name: zhao XX, gender: male, age: age 36
The main symptoms are as follows: the college suffers from hypertension (the highest time can reach 180, the fluctuation is large, and occasionally, dizziness and hypertension are taken as hypotensor), high blood sugar and blood fat, and recently, frequent dizziness, hypodynamia and difficulty in falling asleep.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 4 months.
The treatment results are as follows: when the insomnia therapeutic apparatus is used for 3 days, the sleep is obviously improved, the hypertension drug is stopped, and the condition of dizziness is relieved.
As a result: is obviously effective.
Case 24
Name: wu XX, gender: female, age: 62
The main symptoms are as follows: poor sleep quality, hypopsia, dizziness, chest distress, high blood pressure (taking medicine), poor gastrointestinal absorption function, pain and numbness of waist, neck and shoulder joints, and hospitalization for more than one month in 2 months with light brain peduncles.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 6 months.
The treatment results are as follows: after the insomnia therapeutic apparatus starts to be used in 4 months and 17 days, the sleep is obviously improved and the facial pigment is obviously faded after more than 1 month. After 2 months of use, dizziness, chest distress phenomenon do not exist, gastrointestinal function is improved, and waist and cervical vertebra do not have pain and numbness. The 10-month 14-day CsR examination demonstrated depth scan data for body cells: the curative effects of cardiovascular and cerebrovascular, liver and gallbladder, gastrointestinal function, blood vessel microcirculation repair, waist, neck and shoulder joint pain, vision rehabilitation and the like are obvious.
As a result: is obviously effective.
Case 25
Name: hair XX, gender: male, age: age 63
The main symptoms are as follows: poor sleep quality, cyst in the liver in the early stage (about 10 years), varicose veins (operation before 1 year), and anterior fissure (operation just done this year).
Treatment of the condition: the procedure as mentioned in example 1 was followed for 3 months.
The treatment results are as follows: the sleep quality is much better after 45 days of using the sleep therapeutic apparatus of the invention.
As a result: is obviously effective.
Case 26
Name: tang XX, gender: male, age: x
The main symptoms are as follows: shallow sleep and high blood pressure, 1 blood pressure lowering medicine has been taken daily for 5 years.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 6 months.
The treatment results are as follows: the sleep of the sleep therapeutic apparatus is deeper than before after 1 month, the hypotensor is reduced by half after 3 months of use, and the hypotensor is stopped after 6 months of use.
As a result: is obviously effective.
Case 27
Name: zhao XX, gender: female, age: age 62 years old
The main symptoms are as follows: in recent two years, the traditional Chinese medicine composition has mild symptoms of chest distress and cardiodynia, has poor sleep quality (the traditional Chinese medicine composition can wake up for 2-3 times at 22-6 points), and is always taken by ginkgo leaves.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 12 months.
The treatment results are as follows: 1. the sleep therapeutic apparatus of the invention can sleep more deeply when the patient sleeps for 1 month, basically the patient feels bright after 1 year, 2. the patient stops taking the ginkgo leaves, the symptoms of chest distress and difficulty disappear after half a year, and no cold is caused after 3 years of winter (the patient must catch a cold every year).
As a result: is obviously effective.
Case 28
Name: wu XX, gender: female, age: age 61
The main symptoms are as follows: nephritis, 3 urine proteins, swollen feet, easy sleep and dark face due to deficiency of qi and blood in the face.
Treatment of the condition: the procedure as mentioned in example 1 was followed for half a month of continuous use.
The treatment results are as follows: the sleeping can not be done, the deep sleep time is greatly increased, the qi and blood of the face are greatly changed, and the face is not blackened but ruddy and glossy.
As a result: is obviously effective.
Case 29
Name: XXX, sex: x, age: x
The main symptoms are as follows: the insomnia can only reach 4 hours in average every night due to high working pressure for 10 years, the sleep is fast and early every night, the user can wake up on time basically from 9 o 'clock to 2 o' clock at night, then the user can not fall asleep again, the user can get up in the morning and feel sleepy, the mental state is poor for a long time, and the face is dark and yellow. Often the day is not focused on the yawning day.
Treatment of the condition: the procedure as mentioned in example 1 was followed for 6 months.
The treatment results are as follows: the insomnia sleep therapeutic apparatus of the invention can slowly improve the sleep in about 10 days, the sleep condition begins to be improved in about 20 days, sleepiness begins to be achieved for more than 10 hours at night, and then the insomnia sleep therapeutic apparatus can wake up naturally and has good mental state after 6 hours in the morning. Even if the user wakes up at night, the user can still go to sleep again, and the sleep condition of the last months is always better.
As a result: is obviously effective.
The foregoing shows and describes the general principles and broad features of the present invention and advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are merely illustrative of the principles of the present invention, but that various changes and modifications may be made without departing from the spirit and scope of the invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims.
Claims (10)
1. An insomnia therapeutic apparatus using an integral wave micromagnetic field, comprising an electromagnetic wave generator for applying an electromagnetic wave to a patient, the waveform of the electromagnetic wave being:
<mrow> <mi>I</mi> <mrow> <mo>(</mo> <mi>t</mi> <mo>)</mo> </mrow> <mo>=</mo> <mfenced open = "{" close = ""> <mtable> <mtr> <mtd> <mrow> <mn>0</mn> <mo>,</mo> </mrow> </mtd> <mtd> <mrow> <mi>t</mi> <mo><</mo> <mn>0</mn> </mrow> </mtd> </mtr> <mtr> <mtd> <mrow> <msub> <mi>I</mi> <mi>max</mi> </msub> <mo>&times;</mo> <mrow> <mo>(</mo> <mn>1</mn> <mo>-</mo> <mo>(</mo> <mrow> <mn>1</mn> <mo>/</mo> <msup> <mi>e</mi> <mrow> <mi>t</mi> <mo>/</mo> <mi>&tau;</mi> </mrow> </msup> </mrow> <mo>)</mo> <mo>)</mo> </mrow> <mo>,</mo> </mrow> </mtd> <mtd> <mrow> <mn>0</mn> <mo>&le;</mo> <mi>t</mi> <mo>&le;</mo> <msub> <mi>t</mi> <mn>1</mn> </msub> </mrow> </mtd> </mtr> <mtr> <mtd> <mrow> <mn>0</mn> <mo>,</mo> </mrow> </mtd> <mtd> <mrow> <mi>t</mi> <mo>></mo> <msub> <mi>t</mi> <mn>1</mn> </msub> </mrow> </mtd> </mtr> </mtable> </mfenced> </mrow>
300μsec≤τ≤0.02sec,
5msec≤t1≤0.1sec。
wherein,
τ is equal to the time constant generated by the generator in the drive circuit;
t represents any point in time;
(t1-t) representing pulsesDuration or on-time of the burst;
Imaxrepresenting the maximum DC current flowing through the circuit,
the electromagnetic waves are effective to reduce clinical symptoms in patients with insomnia.
2. The insomnia treatment apparatus of claim 1, wherein Imax is in the range of 50mA ≦ Imax≤200mA。
3. The insomnia treatment apparatus of claim 1, wherein τ and t1The ranges of (A) are as follows:
a)8.15msec≤τ≤12.15msec,
b)42.5msec≤t1≤62.5msec。
4. the insomnia treatment apparatus of claim 1, wherein said electromagnetic wave has a frequency between 20Hz and 120 Hz.
5. An insomnia treatment apparatus according to any one of claims 1-4, wherein said electromagnetic waves are applied to the Yongquan point of the left and right feet and/or the Laogong point of the left and right hands of said patient.
6. The insomnia treatment apparatus of claim 5, wherein said electromagnetic waves are applied to said patient's right and left foot yongquan points and/or right and left hand laogong points at least once a day for 8-20 minutes each.
7. The insomnia therapy apparatus of any one of claims 1-4, wherein said electromagnetic waves are effective to reduce a Zedberg sleep quality index score of a patient suffering from insomnia.
8. The insomnia treatment apparatus of any one of claims 1-4, wherein said electromagnetic waves are used as a monotherapy for treating insomnia.
9. The insomnia treatment apparatus according to any one of claims 1-4, wherein the electromagnetic waves are used as an adjuvant therapy for treating insomnia.
10. The insomnia treatment apparatus of claim 9, wherein said electromagnetic waves are used with a drug for treating insomnia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610409998.XA CN107485790A (en) | 2016-06-13 | 2016-06-13 | It is a kind of to utilize the apparatus for curing insomnia for integrating the micro- magnetic field of ripple |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610409998.XA CN107485790A (en) | 2016-06-13 | 2016-06-13 | It is a kind of to utilize the apparatus for curing insomnia for integrating the micro- magnetic field of ripple |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107485790A true CN107485790A (en) | 2017-12-19 |
Family
ID=60642714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610409998.XA Pending CN107485790A (en) | 2016-06-13 | 2016-06-13 | It is a kind of to utilize the apparatus for curing insomnia for integrating the micro- magnetic field of ripple |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107485790A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110038222A (en) * | 2019-02-22 | 2019-07-23 | 百慕迪(上海)再生医学科技有限公司 | A kind of apparatus for curing insomnia using pulse electromagnetic field |
CN110038221A (en) * | 2019-02-22 | 2019-07-23 | 百慕迪(上海)再生医学科技有限公司 | A kind for the treatment of of metabolic instrument using pulse electromagnetic field |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526888A (en) * | 2012-01-21 | 2012-07-04 | 百慕迪控股有限公司 | Cell excitation treatment instrument for cardiovascular diseases |
-
2016
- 2016-06-13 CN CN201610409998.XA patent/CN107485790A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102526888A (en) * | 2012-01-21 | 2012-07-04 | 百慕迪控股有限公司 | Cell excitation treatment instrument for cardiovascular diseases |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110038222A (en) * | 2019-02-22 | 2019-07-23 | 百慕迪(上海)再生医学科技有限公司 | A kind of apparatus for curing insomnia using pulse electromagnetic field |
CN110038221A (en) * | 2019-02-22 | 2019-07-23 | 百慕迪(上海)再生医学科技有限公司 | A kind for the treatment of of metabolic instrument using pulse electromagnetic field |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100425274C (en) | Insomnia treating Chinese medicine | |
Tiran | Reflexology in pregnancy and childbirth | |
Usui et al. | The Original Reiki Handbook of Dr. Mikao Usui | |
Stillerman | Modalities for massage and bodywork | |
CN107485790A (en) | It is a kind of to utilize the apparatus for curing insomnia for integrating the micro- magnetic field of ripple | |
Rhyner | Ayurveda: The gentle health system | |
Whipple et al. | Male multiple ejaculatory orgasms: A case study | |
Chen et al. | Diagnostics in Chinese medicine | |
Tolba et al. | Effect of acupressure on sleep quality among patients with acute coronary syndrome at assiut university heart hospital | |
Bishop | Health and Aging | |
CN105853880A (en) | Foot bath lotion for treating insomnia and preparation method thereof | |
Wohlgemuth | On the feelings and their neural correlate, with an examination of the nature of pain | |
Patel et al. | Effect of Nasapana in the management of avabahuka WSR to frozen shoulder: A case study | |
Rasale et al. | UTILITY AND IMPORTANCE OF BLOOD AND SHONITAMOKSHANA IN THE VIEW OF CHRONIC DISEASES DESCRIBED IN ANCIENT TEXTS OF MEDICINE | |
Vaghela et al. | AYURVEDIC APPROACH FOR PREVENTION OF NETRA ROGA | |
Korngold et al. | Chinese medicine and the mind | |
Al-Shura | Perspectives of Ayurveda in Integrative Cardiovascular Chinese Medicine for Patient Compliance: Volume 4 | |
Mayo et al. | Menopause Manager, The: A Safe Path for a Natural Change | |
PREU et al. | Symptomatic psychoses in pernicious anemia | |
Miraj et al. | Electronic Physician (ISSN: 2008-5842) http://www. ephysician. ir | |
Kaushik | Bailliere's Dictionary for Nurses and Health Care Workers, 2nd South Aisa Edition-E-Book | |
Pope | Practical Hydrotherapy: A Manual for Students and Practitioners | |
Petrén | Remarks on Sciatica and Morbus Coxæ senilis, especially with regard to their treatment | |
CN107320558A (en) | It is a kind of to treat pharmaceutical composition of insomnia and its production and use | |
Scudder | Specific diagnosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171219 |
|
RJ01 | Rejection of invention patent application after publication |